TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1799911

Group type: EXPERIMENTAL
Intervention: Nitro-Dur Transdermal Infusion System
Number of subjects: 72

Group type: COMPARATOR
Intervention: Transderm-Nitro Transdermal Therapeutic System
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nitro-Dur
Number of subjects: 72
Study: 6230209

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate - 50 mg b.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study: 31734605

Group type: EXPERIMENTAL
Intervention: rs9939049 in CDH1
Number of subjects: 1948
Study: 30770517

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 148
Study: 29246960

Group type: EXPERIMENTAL
Intervention: omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control (no omega-3)
Number of subjects: 285
Study: 26036082

Group type: EXPERIMENTAL
Intervention: Dynamic electrical neurostimulation (DENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard combined treatment (including pharmacotherapy, massage, and therapeutic physical culture exercises)
Number of subjects: 0
Study: 23143710

Group type: EXPERIMENTAL
Intervention: Twin-mix (1.8 ml 2% lignocaine with 1:200,000 epinephrine + 1 ml of 4 mg dexamethasone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lignocaine with 1:200,000 epinephrine
Number of subjects: 20
Study: 22186855

Group type: EXPERIMENTAL
Intervention: Only children
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: First-born children with siblings
Number of subjects: 200

Group type: COMPARATOR
Intervention: Children with siblings (not specified if first-born or later-born)
Number of subjects: 200
Study: 19837909

Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg twice daily, increasing to 50 mg twice daily during the 12-week titration if serum calcium levels were 10.3 mg/dl or higher
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 45
Study: 16946029

Group type: EXPERIMENTAL
Intervention: Adenosine receptor antagonism with aminophylline (Aph)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 19
Study: 14724146

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (HpE group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Omeprazole with placebo antibiotics (Hp+ group)
Number of subjects: 104
Study: 11368990

Group type: EXPERIMENTAL
Intervention: Diary 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diary 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diary 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone-in regimen
Number of subjects: 0
Study: 9402119

Group type: EXPERIMENTAL
Intervention: Rectal tube placement
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard management without tube placement
Number of subjects: 67
Study: 7634265

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2531457

Group type: EXPERIMENTAL
Intervention: Ultrarapid induction (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrarapid induction protected by fentanyl (Group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 60
Study: 31780570

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg every 3 weeks, typically for ≤12 months) combined with front-line chemotherapy (carboplatin/paclitaxel)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg) with chemotherapy
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 299
Study: 30445875

Group type: EXPERIMENTAL
Intervention: Educational video on schizophrenia
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 260
Study: 25951945

Group type: EXPERIMENTAL
Intervention: PMBLs
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 24267002

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) plus anti-thymocyte globulin (ATG) for severe AA (SAA) patients
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) alone for non-severe AA (NSAA) patients
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) plus anti-thymocyte globulin (ATG) for SAA patients
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) alone for NSAA patients
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: ATG plus CsA or CsA alone
Number of subjects: 186
Study: 21723703

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional TKA instrumentation
Number of subjects: 208
Study: 18563416

Group type: EXPERIMENTAL
Intervention: CT findings associated with WOPN
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CT score of 2 or higher
Number of subjects: 73

Group type: COMPARATOR
Intervention: Presence of pancreatic duct dilation
Number of subjects: 73
Study: 17214260

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser stapedotomy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Microdrill stapedotomy
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Both techniques (laser and microdrill)
Number of subjects: 336
Study: 14727235

Group type: EXPERIMENTAL
Intervention: RCT plus amifostine (300 mg/m(2) daily intravenous infusion)
Number of subjects: 73

Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 73
Study: 10741446

Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography (IOC) performed in 435 patients (87%)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Postoperative pancreatitis
Number of subjects: 500
Study: 8638338

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 225
Study: 1852797

Group type: EXPERIMENTAL
Intervention: Training once every other week (n = 10)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Training once per week (n = 12)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Training twice per week (n = 12)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Training three times per week (n = 7)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nontraining control group (n = 15)
Number of subjects: 56
Study: 6864403

Group type: EXPERIMENTAL
Intervention: Banked human milk (BHM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Protein‐mineral‐calorie‐enriched formula (Similac Special Care)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 30862193

Group type: EXPERIMENTAL
Intervention: TX-004HR (4, 10, or 25 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28653345

Group type: EXPERIMENTAL
Intervention: Intravenous bimagrumab 30 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26764182

Group type: EXPERIMENTAL
Intervention: Intensive enteral nutrition plus methylprednisolone
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional nutrition plus methylprednisolone (controls)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both groups (regardless of intervention)
Number of subjects: 136
Study: 24432712

Group type: EXPERIMENTAL
Intervention: EXAcerbations of Chronic Pulmonary Disease Tool (EXACT)
Number of subjects: 1581
Study: 22528280

Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (medical management)
Number of subjects: 47
Study: 19914571

Group type: EXPERIMENTAL
Intervention: Medical compression stocking (TED)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 295
Study: 17307412

Group type: EXPERIMENTAL
Intervention: Early abciximab administration before transfer to catheterization laboratory (27 patients)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Late abciximab administration immediately before PPCI (32 patients)
Number of subjects: 59
Study: 15011245

Group type: EXPERIMENTAL
Intervention: Endovaginal coil MR imaging at 1.5 T with T(1)‐ and T(2)‐weighted scans
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ex vivo analysis using MAS‐MR spectroscopy
Number of subjects: 53
Study: 11685730

Group type: EXPERIMENTAL
Intervention: Docetaxel and exisulind combination therapy
Number of subjects: 0
Study: 9593960

Group type: EXPERIMENTAL
Intervention: fMRI during picture naming task for animals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: fMRI during picture naming task for furniture items
Number of subjects: 12
Study: 9059766

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a low-calorie diet and metformin 1,700 mg/day
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 82
Study: 2759222

Group type: EXPERIMENTAL
Intervention: Methoxamine (Mx)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study: 73014

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30905926

Group type: EXPERIMENTAL
Intervention: Metformin combined group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insulin group (Control)
Number of subjects: 80
Study: 28854929

Group type: EXPERIMENTAL
Intervention: F-75 to RUTF transition
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Age of child
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Caregiver assessment of illness severity
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: RUTF acceptance
Number of subjects: 341
Study: 25822991

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study: 23512355

Group type: EXPERIMENTAL
Intervention: Eculizumab for 16 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22256635

Group type: EXPERIMENTAL
Intervention: Thoroughfare Vessel theory acupuncture (Dazhu (BL 11), Shangjuxu (ST 37), Xiajuxu (ST 39), Neiguan (PC 6), Gongsun (SP 4))
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional acupuncture (Fengchi (GB 20), Lianquan (CV 23), Tiantu (CV 22), Neiguan (PC 6), Zusanli (ST 36))
Number of subjects: 78
Study: 18500521

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg twice per day, 4 days before and on the day of chemotherapy (cohort 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dexamethasone 16 mg twice per day, 4 days before and on the day of chemotherapy (cohort 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No dexamethasone (cohort 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall effect of dexamethasone
Number of subjects: 30
Study: 16702889

Group type: EXPERIMENTAL
Intervention: Higher dose venlafaxine ER (mean dose = 309 mg/d)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Standard dose venlafaxine ER (mean dose = 148 mg/d)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Higher dose venlafaxine ER
Number of subjects: 232

Group type: COMPARATOR
Intervention: Standard dose venlafaxine ER
Number of subjects: 232
Study: 15373931

Group type: COMPARATOR
Intervention: bezafibrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: fenofibrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10884467

Group type: EXPERIMENTAL
Intervention: GRE‐EPI
Number of subjects: 198
Study: 9288840

Group type: EXPERIMENTAL
Intervention: CHART (54 Gy in 36 fractions over 12 days)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Conventional radiotherapy (66 Gy in 33 fractions over 6.5 weeks)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 918

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 918
Study: 8321736

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All dosage groups of ramipril and enalapril
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Ramipril (all dosages)
Number of subjects: 159
Study: 3759915

Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of oxazepam in capsule form
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of oxazepam in tablet form
Number of subjects: 17
Study: 29933113

Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (D-RES; 15 kcal·kg LBM‐1·d‐1)
Number of subjects: 10
Study: 27629738

Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (Group I, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No perioperative antibiotic therapy (Group II, n = 25)
Number of subjects: 50
Study: 25013787

Group type: EXPERIMENTAL
Intervention: Roux-Y FBPJ
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hand-sewn closure
Number of subjects: 47
Study: 22860693

Group type: EXPERIMENTAL
Intervention: Regular hypotonic ORS (Na 60 mmol/L, glucose 78 mmol/L)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Apple-flavoured hypotonic ORS (same composition as regular ORS)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Regular hypotonic ORS
Number of subjects: 147

Group type: COMPARATOR
Intervention: Apple-flavoured hypotonic ORS
Number of subjects: 147
Study: 20815864

Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale (SWLS)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Life Satisfaction Questionnaire (LISAT-9)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Personal Well-Being Index (PWI)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 5-item World Health Organization Quality of Life Assessment (WHOQoL-5)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Post-hoc procedures applied to WHOQoL-5 and PWI
Number of subjects: 243
Study: 18822473

Group type: EXPERIMENTAL
Intervention: Inhalational fusafungine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Systemic antibiotics (per os or parenteral)
Number of subjects: 100
Study: 15792513

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (HYPO) (32-33 degrees C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normothermia (NORM) (36.5-37.5 degrees C)
Number of subjects: 48
Study: 12500983

Group type: EXPERIMENTAL
Intervention: MILK
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 9
Study: 10087687

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Systemic behavioral family therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Nondirective supportive therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study: 7500603

Group type: EXPERIMENTAL
Intervention: Microagglutination test
Number of subjects: 30
Study: 1973583

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (4 mg) intravenously injected
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 304522

Group type: EXPERIMENTAL
Intervention: Paracetamol syrup
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Paracetamol suppositories
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination of paracetamol with doxylaminsuccinate
Number of subjects: 144
Study: 31023125

Group type: EXPERIMENTAL
Intervention: Age 45 years
Number of subjects: 4072

Group type: EXPERIMENTAL
Intervention: Age 65 years
Number of subjects: 4072
Study: 28134753

Group type: EXPERIMENTAL
Intervention: Collaborative Beamforming (CB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxed requirements for CB
Number of subjects: 0
Study: 25701046

Group type: EXPERIMENTAL
Intervention: Lyric analysis intervention using 'Hurt' or 'How to Save a Life'
Number of subjects: 104

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 104
Study: 23623339

Group type: EXPERIMENTAL
Intervention: 5mg/kg ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 mcg/kg dexmedetomidine
Number of subjects: 60
Study: 21791356

Group type: EXPERIMENTAL
Intervention: 100 units of onabotulinum toxin A
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 300 units of onabotulinum toxin A
Number of subjects: 134
Study: 19154492

Group type: EXPERIMENTAL
Intervention: Non-invasive management (NIM) with immediate empirical antibiotic treatment (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Invasive management (IM) based on protected brush sampling of specimens (n = 34)
Number of subjects: 68
Study: 17451425

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/40 mg
Number of subjects: 661

Group type: COMPARATOR
Intervention: ATV 20 mg
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg, EZE/SIMVA 10/40 mg, ATV 20 mg
Number of subjects: 661
Study: 15070662

Group type: EXPERIMENTAL
Intervention: FLAG (Fludarabine + ARA-C + G-CSF)
Number of subjects: 134

Group type: COMPARATOR
Intervention: AG (ARA-C + G-CSF)
Number of subjects: 134
Study: 11419672

Group type: EXPERIMENTAL
Intervention: Aminopenicillins at the correct dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macrolides and fluoroquinolones
Number of subjects: 0
Study: 9431610

Group type: EXPERIMENTAL
Intervention: High-dose traction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sham (low-dose) traction
Number of subjects: 151
Study: 8214532

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (150 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bupivacaine 0.75% (112.5 mg)
Number of subjects: 44
Study: 3658314

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 20
Study: 31280941

Group type: EXPERIMENTAL
Intervention: Modified External Rotation Method (MERM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: External Rotation Method (ERM)
Number of subjects: 62
Study: 29565666

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system (in male participants)
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 4407
Study: 27580443

Group type: EXPERIMENTAL
Intervention: PSSIB (Palmar Subcutaneous Single Injection Block)
Number of subjects: 190

Group type: COMPARATOR
Intervention: DTIB (Dorsal 2 Injection Block)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: PSSIB
Number of subjects: 190

Group type: COMPARATOR
Intervention: DTIB
Number of subjects: 190
Study: 25141962

Group type: EXPERIMENTAL
Intervention: Laser therapy (indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm) applied five days a week before each radiotherapy session.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo applied five days a week before each radiotherapy session.
Number of subjects: 52
Study: 24251745

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (4-min cycle ergometer exercise at 80% of ventilation threshold)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (untrained females)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise
Number of subjects: 18
Study: 20452927

Group type: EXPERIMENTAL
Intervention: Curriculum infusion (CI) in treatment classes
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control group (no curriculum infusion)
Number of subjects: 343
Study: 18370832

Group type: EXPERIMENTAL
Intervention: Obesity (measured by waist circumference and total body fat percentage)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Normal weight subjects
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 550
Study: 16572301

Group type: EXPERIMENTAL
Intervention: Behavior observation in training intervention agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior observation in delivery of key intervention conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring client responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring short-term risk reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior observation in measuring long-term change
Number of subjects: 0
Study: 14517785

Group type: EXPERIMENTAL
Intervention: 4 mg/kg intravenous cyclosporine
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2 mg/kg intravenous cyclosporine
Number of subjects: 73
Study: 10379634

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isradipine SRO (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spirapril (6 mg)
Number of subjects: 0
Study: 8884757

Group type: EXPERIMENTAL
Intervention: 30 mg vincamine twice daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 1647531

Group type: EXPERIMENTAL
Intervention: High compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Medium compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low compliance enhancement group (wheat bran fiber supplement 18 g/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Comprehensive compliance enhancement group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study: 6195201

Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 6 hours
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 12 to 24 hours
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: 1% gamma benzene hexachloride (GBH) lotion applied for 2 hours
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Control group (untreated persons with scabies)
Number of subjects: 2076